Results 71 to 80 of about 4,040 (201)

NCY‐1 β‐Lactamase Activity Correlates With Antimicrobial Susceptibility of a Clinical Strain of Nocardia cyriacigeorgica

MicrobiologyOpen, Volume 15, Issue 2, April 2026.
This study shows a strong correlation between the β‐lactam susceptibility profile of a clinical isolate of Nocardia cyriacigeorgica and the activity of its β‐lactamase, NCY‐1. Inhibitors of NCY‐1 reduce the minimum inhibitory concentration of amoxicillin.
Julie Couston, Athénaïs Le Marchand, Elisabeth Hodille, Charlotte Genestet, Brune Joannard, Jérôme Feuillard, Yvonne Benito, Oana Dumitrescu, Mickaël Blaise   +8 more
wiley   +1 more source

Reversing Antibiotic Resistance: Strategies From Adjuvants to Innovative Therapeutics

MicrobiologyOpen, Volume 15, Issue 1, February 2026.
Molecular reversal strategies against antibiotic resistance act through three mechanisms: inhibiting resistance gene function, blocking horizontal gene transfer, and modulating host defense. Emerging technologies, such as CRISPR‐Cas gene editing, photodynamic therapy, nanotechnology, and ecological competition, further strengthen these approaches ...
Tianjiao Li, Fei Zeng, Jie Zhang, Yuangong Zhang, Wenjuan Yin   +4 more
wiley   +1 more source

Clinical Epidemiological Analysis of the Genotypic Spectrum and Mortality Risk in Carbapenem‐Resistant Klebsiella pneumoniae (CRKP) Infections

Canadian Journal of Infectious Diseases and Medical Microbiology, Volume 2026, Issue 1, 2026.
Background Carbapenem‐resistant Klebsiella pneumoniae (CRKP) has become a global public health threat, with significantly increased morbidity and mortality among high‐risk inpatients. High‐risk genotypes of CRKP, primarily including K. pneumoniae carbapenemase (KPC), oxacillinase‐48–like (OXA‐48–like), New Delhi metallo‐β‐lactamase (NDM), imipenemase ...
Qiongfang Zhang, Ze Fang, Bo Fang, Hailing Zeng, Jiaojiao Xu, Muhammad Abu Bakr Shabbir   +5 more
wiley   +1 more source

Correction to: Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections [PDF]

Drugs, 2018
The article Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections.
openaire   +2 more sources

Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae

Infection and Drug Resistance, 2018
Lindsay A Petty,1 Oryan Henig,1 Twisha S Patel,2 Jason M Pogue,3 Keith S Kaye1 1Department of Internal Medicine, Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, MI, USA; 2Department of Pharmacy Services, University of ...
Petty LA, Henig O, Patel TS, Pogue JM, Kaye KS   +4 more
doaj  

Antibiotic Resistance: A Genetic and Physiological Perspective

MedComm, Volume 6, Issue 11, November 2025.
The development of resistance to antimicrobials and their historical progression are depicted in this graphic. It draws attention to important biochemical, physiological, and genetic factors that contribute to AMR, such as the transmission of genes, the development of biofilms, and the inactivation of antibiotics.
Rania G. Elbaiomy, Ahmed H. El‐Sappah, Rong Guo, Xiaoling Luo, Shiyuan Deng, Meifang Du, Xiaohong Jian, Mohammed Bakeer, Zaixin Li, Zhi Zhang   +9 more
wiley   +1 more source

Antibiotic Therapy Strategies for Treating Gram-Negative Severe Infections in the Critically Ill: A Narrative Review [PDF]

, 2023
Introduction: Not enough data exist to inform the optimal duration and type of antimicrobial therapy against GN infections in critically ill patients. Methods: Narrative review based on a literature search through PubMed and Cochrane using the following ...
Agarossi A., Bonetti G., Cattaneo D., Corona A., De Santis V., Latronico N., Patroni A., Prete A., Tomasini G.   +8 more
core   +1 more source

Real-world clinical outcomes of meropenem/vaborbactam for treatment of carbapenem-resistant Enterobacterales infections

Journal of Global Antimicrobial Resistance, 2021
Real-world data regarding the effectiveness of meropenem/vaborbactam (MVB) in the treatment of carbapenem-resistant Enterobacterales (CRE) infections remain limited. In this retrospective case series, we describe the outcomes of patients who received MVB for serious CRE infections.This study included adult patients with MVB-susceptible CRE infection ...
Helen L. Zhang, Leigh Cressman, Ebbing Lautenbach   +2 more
openaire   +3 more sources

A molecular analysis of meropenem-vaborbactam non-susceptible KPC-producing Klebsiella pneumoniae. [PDF]

Antimicrob Agents Chemother
ABSTRACT We characterized the molecular determinants of meropenem–vaborbactam (MV) non-susceptibility among non-metallo-β-lactamase-producing KPC- Klebsiella pneumoniae (KPC- KP ).
Yasmin M, Marshall SH, Chen L, Rhoads DD, Jacobs MR, Rojas LJ, Perez F, Hujer AM, Hujer KM, van Duin D, Fowler V, Chambers HF, Kreiswirth BN, Bonomo RA, Antibacterial Resistance Leadership Group.   +14 more
europepmc   +3 more sources

Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections [PDF]

, 2020
Fourty patients were treated with meropenem-vaborbactam (MEV) for serious Gram-negative bacterial (GNB) infections. Carbapenem-resistant Enterobacteriaceae (CRE) comprised 80.0% of all GNB infections.
Allen, David, Alosaimy, Sara, Athans, Vasilios, Carlson, Travis J, Davis, Susan L, Garey, Kevin W, Jorgensen, Sarah CJ, Lagnf, Abdalhamid M, Melvin, Sarah, Mynatt, Ryan P, Rybak, Michael J, Saw, Stephen, Venugopalan, Veena, Veve, Michael, Yost, Christine N   +14 more
core   +1 more source